This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Aliskiren (EU: Rasilez)/valsartan, Tekturna/Diovan, Rasival (EU)
Tekturna and Diovan target the renin-angiotensin-aldosterone system. Tekturna blocks renin, an enzyme secreted by the kidney in response to decreases in blood volume and renal perfusion. Renin cleaves angiotensinogen to form the inactive decapeptide angiotensin I (Ang I). Ang I is converted to the active octapeptide angiotensin II (Ang II) by angiotensin-converting enzyme (ACE) and non-ACE pathways. Ang II, whose receptor is blocked by Diovan, is a powerful vasoconstrictor and leads to the release of catecholamines from the adrenal medulla and prejunctional nerve endings. It also promotes aldosterone secretion and sodium reabsorption, which increases volume in the vascular system. Together, these effects increase blood pressure.
Deal Structure: Novartis out-licensed SPP100 (Tekturna) to Speedel for development with a callback option. Novartis exercised this callback option in June 2002 after Speedel had successfully developed SPP100 through Phase I and II.
In September 2008, Speedel was acquired by Novartis.
Partners: Noden Pharma DAC
Pink Sheet Novartis withdraws EU Rasival submission
Additional information available to subscribers only: